Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 4,942	$ 10,991
General and administrative	4,622	5,132
Total operating expenses	9,564	16,123
Loss from operations	(9,564)	(16,123)
Other income:
Other income	1,138	1,016
Net loss	(8,426)	(15,107)
Unrealized (loss) gain on short-term investments	(20)	55
Comprehensive loss	$ (8,446)	$ (15,052)
Net loss per share attributable to common stockholders, basic	$ (0.25)	$ (0.6)
Net loss per share attributable to common stockholders, diluted	$ (0.25)	$ (0.6)
Weighted-average shares used in computing net loss per share, basic	33,420,808	25,036,410
Weighted-average shares used in computing net loss per share, diluted	33,420,808	25,036,410